Literature DB >> 2106980

Stopping steroids in polymyalgia rheumatica and giant cell arteritis.

V Kyle1, B L Hazelman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2106980      PMCID： PMC1662131          DOI： 10.1136/bmj.300.6721.344

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  22 in total

1.  Prognosis in the anarthritic rheumatoid syndrome.

Authors:  L BAGRATUNI
Journal:  Br Med J       Date:  1963-02-23

2.  Myalgic syndrome with constitutional effects; polymyalgia rheumatica.

Authors:  H S BARBER
Journal:  Ann Rheum Dis       Date:  1957-06       Impact factor: 19.103

3.  A prospective study of 102 patients with the polymyalgia rheumatica syndrome.

Authors:  E N Coomes; R M Ellis; A G Kay
Journal:  Rheumatol Rehabil       Date:  1976-11

4.  Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  B Dasgupta; O Duke; A M Timms; C Pitzalis; G S Panayi
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

5.  Clinical usefulness of temporal artery biopsy.

Authors:  J Vilaseca; A González; M C Cid; J Lopez-Vivancos; A Ortega
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

6.  Treatment of polymyalgia rheumatica.

Authors:  H Spiera; S Davison
Journal:  Arthritis Rheum       Date:  1982-01

7.  Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).

Authors:  G Delecoeuillerie; P Joly; A Cohen de Lara; J B Paolaggi
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

8.  Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.

Authors:  T Y Chuang; G G Hunder; D M Ilstrup; L T Kurland
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

9.  Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.

Authors:  M De Silva; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

10.  Decrease of the OKT8 positive T cell subset in polymyalgia rheumatica. Lack of correlation with disease activity.

Authors:  C Benlahrache; P Segond; L Auquier; J P Bouvet
Journal:  Arthritis Rheum       Date:  1983-12
View more
  12 in total

Review 1.  Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature.

Authors:  Nádia Emi Aikawa; Rosa Maria Rodrigues Pereira; Laís Lage; Eloisa Bonfá; Jozélio Freire Carvalho
Journal:  Clin Rheumatol       Date:  2012-01-11       Impact factor: 2.980

Review 2.  Corticosteroids and osteoporosis.

Authors:  R Smith
Journal:  Thorax       Date:  1990-08       Impact factor: 9.139

3.  Giant cell arteritis.

Authors:  J C Mason; M J Walport
Journal:  BMJ       Date:  1992-07-11

4.  Plasma viscosity or erythrocyte sedimentation rate in the diagnosis of giant cell arteritis?

Authors:  G P Brittain; G G McIlwaine; J A Bell; J M Gibson
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

5.  Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis.

Authors:  D Caplanne; J M Le Parc; J A Alexandre
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

Review 6.  Clinical features of polymyalgia rheumatica and giant cell arteritis.

Authors:  Carlo Salvarani; Nicolò Pipitone; Annibale Versari; Gene G Hunder
Journal:  Nat Rev Rheumatol       Date:  2012-07-24       Impact factor: 20.543

Review 7.  [Glucocorticoids: importance in the treatment of vasculitis].

Authors:  P M Aries; B Hellmich; W L Gross
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

8.  The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.

Authors:  S Schreiber; M Buyse
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

9.  Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.

Authors:  C Salvarani; L Boiardi; P Macchioni; F Rossi; P Tartoni; M Casadei Maldini; R Mancini; E Beltrandi; I Portioli
Journal:  Ann Rheum Dis       Date:  1995-08       Impact factor: 19.103

10.  Giant cell arteritis and mortality.

Authors:  R Wade Crow; Bradley J Katz; Judith E A Warner; Stephen C Alder; Kang Zhang; Susan Schulman; Kathleen B Digre
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-04       Impact factor: 6.053
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.